The EXPAREL is a bupivacaine liposome injectable suspension which is infiltrated via the TAP. The data will be presented at the annual American Society of Regional Anesthesia and Pain Medicine meeting in November.
Twenty-four patients were evaluated for the study after undergoing robotic prostatectomy with EXPAREL via TAP infiltration. On average, these patients required less than one oxycodone tablet per day from discharge to the 10-day visit. One hundred percent of subjects also reported being satisfied or extremely satisfied with the postsurgical pain control.
More Articles on Anesthesia:
Buretrol Solution Sets From Baxter Healthcare Recalled
Study Shows Brain’s Distinct Electrical Activity While Under Anesthesia
Tillamook County General Hospital Adds Dr. Gregory Opdahl
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
